IRD
Live chart
What they do
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Grades vs sector
MomentumNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.62 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.71 vs trailing $-1.27. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 4/9 · last two fiscal years
Altman Z-score -2.7 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $14.2M | $-49.6M | $-35.3M |
| 2024 | $11.0M | $-57.5M | $-25.6M |
| 2023 | $19.0M | $-10.0M | $-1.1M |
| 2022 | $39.9M | $17.9M | $14.3M |
| 2021 | $589.0K | $-56.7M | $-19.4M |
| 2020 | $0 | $-24.6M | $-6.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -29.1%.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.16 | -0.08 | +49.3% |
| 2026-05-12 | -0.14 | -0.75 | -448.8% |
| 2026-03-10 | -0.10 | -0.21 | -110.0% |
| 2025-11-12 | -0.13 | -0.25 | -92.3% |
| 2025-08-13 | -0.26 | -0.12 | +53.8% |
| 2025-05-15 | -0.20 | -0.24 | -17.1% |
| 2025-03-31 | -0.34 | -0.23 | +32.4% |
| 2024-11-12 | -0.23 | -0.29 | -27.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $755.0K | -73.8% |
| 2026-03-31 | $2.2M | – |
| 2025-12-31 | $3.9M | – |
| 2025-09-30 | $3.1M | – |
| 2025-06-30 | $2.9M | – |
Analyst actions
PT $17
PT $17
PT $16
PT $13
PT $20
PT $8
Stats refreshed 2026-10-21 01:31:58 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.